CTLA4 and neoplasm: In mice, OncoVEXmGM-CSF (mT-VEC) in combination with anti-CTLA-4 significantly extended survival compared to single treatments alone in both A20 and CT-26 bilateral tumor models, with a significant increase in tumor-specific splenocytes [28].